No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir

Antiviral Therapy

Volumn 18, Issue 3, 2013, Pages 321-327

  Baroncelli, Silvia ^a   Mezzaroma, Ivano ^b   Fantauzzi, Alessandra ^b   Galluzzo, Clementina M ^a   Degli Antoni, Anna ^c   Vullo, Vincenzo ^d   Francisci, Daniela ^e   Ladisa, Nicoletta ^f   Vivarelli, Angela ^g   Cirioni, Oscar ^h   Sighinolfi, Laura ⁱ   Weimer, Liliana E ^a   Fragola, Vincenzo ^a   Fidanza, Rina ^b   Cara, Andrea ^a   Palmisano, Lucia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g PISTOIA HOSPITAL   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ S ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CD23 ANTIGEN; CD45RO ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; ENFUVIRTIDE; EXTRACTABLE NUCLEAR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LA ANTIGEN; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SM RIBONUCLEOPROTEIN ANTIGEN; SMOOTH MUSCLE ANTIBODY; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RECEPTORS, IGE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84878080666     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2433     Document Type: Article

References (19)

1. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
2. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
3. Beck-Engeser GB, Eilat D, Harrer T, Jäck HM, Wabl M. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc Natl Acad Sci U S A 2009; 106:20865-20870.
4. Dreyfus DH. Autoimmune disease: a role for new anti-viral therapies? Autoimmun Rev 2011; 11:88-97.
5. Acharya M, Borland G, Edkins AL, et al. CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol 2010; 162:12-23.
6. Bucciardini R, D'Ettorre G, Baroncelli S, et al. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS 2012; 23:459-463.
7. Castro KG, Ward JW, Slutsker L, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Repcomm Rep 1992; 41:1-19.
8. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21:404-410.
9. Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 2006; 19:20-25. (Pubitemid 43032435)
10. Rawson PM, Molette C, Videtta M, et al. Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med 2007; 13:1431-1439. (Pubitemid 350224247)
11. Stratton R, Slapak G, Mahungu T, Kinloch-de Loes S. Autoimmunity and HIV. Curr Opin Infect Dis 2009; 22:49-56.
12. Melek M, Jones JM, O'Dea MH, et al. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc Natl Acad Sci U S A 2002; 99:134-137. (Pubitemid 34060329)
13. Zhang KS, Modi GM, Hsu S. DRESS syndrome associated with raltegravir. Dermatol Online J 2011; 17:14.
14. Isentress (raltegravir). Highlights of prescribing information 2007. Merck Sharpe and Dohme, Whitehouse Station, NJ, USA.
15. Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 2010; 10:470-478.
16. Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011; 20:1303-1314.
17. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908. (Pubitemid 40941873)
18. Martinez V, Diemert MC, Braibant M, et al. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis 2009; 48:123-132.
19. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 28 February 2012. Accessed 05 April 2012.) Available from http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf